NCT02992223已完成不适用
Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant
A.O.U. Città della Salute e della Scienza0 个研究点目标入组 58 人开始时间: 2014年7月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 58
- 主要终点
- Overall Survival
研究概览
简要总结
Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •High Risk Relapsed/refractory aggressive non-hodgkin lymphoma defined as:
- •Progressive disease
- •Early relapse (within 12 months from response)
- •Recurrent relapse
- •Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus high-dose chemotherapy and Autologous stem cell transplant
- •Age > 18 years
- •Previous treatment with Rituximab
- •Written informed consent
排除标准
- •Patient with no complete data available for collection
结局指标
主要结局
Overall Survival
时间窗: Date of last follow-up for at least 18 months (up to 78 months)
Time to last follow-up or death
Progression Free Survival
时间窗: From first response to last follow-up for at least 18 month (up to 78 months)
Time from last response to nearest relapse or follow-up
次要结局
未报告次要终点
研究者
Barbara Botto
MD
A.O.U. Città della Salute e della Scienza
相似试验
已完成
不适用
Radioimmunotherapy with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin LymphomaCancerISRCTN36210045Foundation for the Study of hematology in Aragon [Fundación para el Estudio de la Hematologia y Hemoterapia en Aragón](FEHHA)50
已完成
3 期
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line ChemotherapyLymphoma, Non-HodgkinNCT00185393Bayer414
已完成
1 期
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaStage III Adult Burkitt LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Burkitt LymphomaStage IV Adult Diffuse Large Cell LymphomaWaldenström MacroglobulinemiaPost-transplant Lymphoproliferative DisorderNCT00064246National Cancer Institute (NCI)28
已完成
2 期
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin LymphomasPrimary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's LymphomaNCT00521560Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH28
已完成
2 期
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00336843Asan Medical Center19